Catalysing the development and introduction of paediatric drug formulations: a new global collaborative framework for action  
Penazzato, Watkins, Morin, Lewis, Pascual, Vicari, Lee, Hargreaves, Doherty & Siberry 
The Lancet HIV, 2018, 5(5): 259-e264 

Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries  
Penazzato, Lewis, Watkins, Prabhu, Pascual, Auton, Kreft, Morin, Vicari, Lee, Jamieson & Siberry J Int AIDS Soc, 2018, 21(S1), e25049 

Rome Action Plan  

The Rome Action Plan is a compilation of commitments by key stakeholders to accelerate research, development, registration, introduction and uptake of HIV & TB diagnostics and medicines for children, with the ultimate objective of reducing morbidity and mortality. 

Accelerate progress towards reducing maternal, newborn and child mortality in order to achieve Sustainable Development Goal targets 3.1 and 3.2

Paludisme: nouvelle résistance au traitement chez les enfants
Le Monde, 20 November 2024

The Global Accelerator for Paediatric Formulations (GAP-f)

Accelerating the development and uptake of the most needed drug formulations for children 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology – Morin, Cohn, Vicari, Domanico, Lewis, Watkins, Pascual, Lee, Sugandhi, Eisenhawer, Pérez Casas, Auton, Siberry, Giaquinto, Penazzato, On behalf of GAP-f partners — March 2018 | Granada, Spain

Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations
Cressey, Abbassi, Lallemant, Indolfi, Al-Nahari, Farid, Penazzato, Easterbrook & El-Sayed – PIDJ, 2021, 40(12): 1081-1086

Enpr-EMA – European Network of Paediatric Research at the European Medicines Agency  
Network of research networks, investigators and centres with recognised expertise in performing clinical studies in childrens

GPFC – Goodman Pediatric Formulations Centre (GPFC) 
Rosalind & Morris Goodman Family Pediatric Formulations Centre of the CHU Sainte-Justine 

LEAP – Long-Acting / Extended Release Antiretroviral Resource Program  
Portal funded by the U.S. National Institutes of Health 

MAP-IT Model – Model for Assessment of Pediatric Interventions for Tuberculosis  
RTI International, TB Alliance, Unitaid 

Paed Form – European Paediatric Formulary  
Council of Europe 

Pediatric COVID-19 therapeutics: Seizing the right research and development opportunities to accelerate access for children
Morin, Lallemant, Garcia-Prats, Lewis, Watkins, Giaquinto, Valentin, Penazzato & Reeder – PIDJ, 2022, 41(1): e1-e5

STEP database – Safety & Toxicity of Excipients for Paediatrics 
European Paediatric Formulation Initiative 

USPFI – United States Pediatric Formulation Initiative  
In the context of the Best Pharmaceuticals for Children Act (BPCA) and with groups focused on scientific/technical/regulatory barriers, taste/smell/flavour, economics/partnerships, and use/application of new delivery systems 

Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations
Cressey, Abbassi, Lallemant, Indolfi, Al-Nahari, Farid, Penazzato, Easterbrook & El-Sayed – PIDJ, 2021, 40(12): 1081-1086

Expression of Interest for product evaluation

This table below lists paediatric medicines included in the Invitation to Manufacturers to Submit an Expressions of Interest (EOI) for Product Evaluation by WHO Prequalification. Only dosage forms specifically developed for paediatric use are included. Dosage forms not specifically formulated for paediatric patients—such as intravenous (IV) formulations, which do not typically require child-specific adaptations—are not included.